Prof Helen Fletcher
Scientific Innovation Lead
Johnson & Johnson
Network Investigator, VALIDATE Co-Director 2017-2021, Management Team Member 2017-2021, Network Management Board Member 2017-2021
Inate immunity, T cell immunology, vaccines, disease control, global health, immunisation, TB, malaria
I gained a PhD in Medical Microbiology from the University of Leeds and became interested in tuberculosis (TB) in 1999 during my first postdoctoral position at University College London. In 2002 I moved to the Jenner Institute at the University of Oxford as an immunologist for the first-in-man trial of a new TB vaccine, MVA85A. After 10 years at the Jenner Institute I moved to the London School of Hygiene & Tropical Medicine to establish my group, based in the Immunology and Infection Department, which focuses on immune correlates and the host response to TB vaccination. In 2015 I became Director of the TB Centre at the London School of Hygiene & Tropical Medicine and in 2016 I became co-chair of the T-cell Immunology working group for the Collaboration for TB Vaccine Discovery (CTVD) at the Bill & Melinda Gates Foundation.
Profile page at LSHTM
T-cell activation is an immune correlate of risk in BCG vaccinated infants. Fletcher, H.A. ; Snowden, M.A. ; Landry, B. ; Rida, W. ; Satti, I. ; Harris, S.A. ; Matsumiya, M. ; Tanner, R. ; O'Shea, M.K. ; Dheenadhayalan, V. ; Bogardus, L. ; Stockdale, L. ; Marsay, L. ; Chomka, A. ; Harrington-Kandt, R. ; Manjaly-Thomas, Z.R. ; Naranbhai, V. ; Stylianou, E. ; Darboe, F. ; Penn-Nicholson, A. ; Nemes, E. ; Hatheril, M. ; Hussey, G. ; Mahomed, H. ; Tameris, M. ; McClain, J.B. ; Evans, T.G. ; Hanekom, W.A. ; Scriba, T.J. ; McShane, H. ; Nat Commun
Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. Fletcher, H.A.; Filali-Mouhim, A.; Nemes, E.; Hawkridge, A.; Keyser, A.; Njikan, S.; Hatherill, M.; Scriba, T.J.; Abel, B.; Kagina, B.M.; Veldsman, A.; Agudelo, N.M.; Kaplan, G.; Hussey, G.D.; Sekaly, R.P.; Hanekom, W.A.; BCG study team, .; COLLABORATORS;Minnies, D. ; Tanner, R. ; Chung, C.K. ; Cameron, M.J. ; Goulet, J.P. ; Gaujoux, R. ; Hughes, J. ; Gelderbloem, S. ; Iloni, K. ; Buchanan, M. ; van der Merwe, L. ; Burger, A. ; Denation, L. ; Mlanjeni, S. ; Abrahams, S. ; Shepherd, R. ; Geldenhuys, M. ; Seoighe, C. ; Soares, A. ; Gamieldien, H. ; Sidibana, M. ; Mahomed, H. ; McShane, H. ; Hill, A.V. ; BMC Med
Human biomarkers: can they help us to develop a new tuberculosis vaccine? Fletcher, H.A.; Dockrell, H.M.; Future Microbiol
Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Dunachie, S. ; Berthoud, T. ; Hill, A.V. ; Fletcher, H.A. ; Vaccine
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. Naranbhai, V. ; Fletcher, H.A. ; Tanner, R. ; O'Shea, M.K. ; McShane, H. ; Fairfax, B.P. ; Knight, J.C. ; Hill, A.V. ; EBioMedicine
Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model. Matsumiya, M. ; Satti, I. ; Chomka, A. ; Harris, S.A. ; Stockdale, L. ; Meyer, J. ; Fletcher, H.A. ; McShane, H. ; J Infect Dis
Blood monocyte-lymphocyte ratios identify adults at risk of incident tuberculosis amongst patients initiating antiretroviral therapy.
Naranbhai, V.; Hill, A.V.; Abdool Karim, S.S.; Naidoo, K.; Abdool Karim, Q.; Warimwe, G.M.; McShane, H.; Fletcher, H.; J Infect Dis
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. McShane, H. ; Pathan, A.A. ; Sander, C.R. ; Keating, S.M. ; Gilbert, S.C. ; Huygen, K. ; Fletcher, H.A. ; Hill, A.V. ; Nat Med